Overview

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hussein Tawbi
University of Pittsburgh
Collaborators:
Eisai Inc.
Schering-Plough
Treatments:
Azacitidine
Dacarbazine
Decitabine
Temozolomide